JP2020522269A5 - - Google Patents

Download PDF

Info

Publication number
JP2020522269A5
JP2020522269A5 JP2019567677A JP2019567677A JP2020522269A5 JP 2020522269 A5 JP2020522269 A5 JP 2020522269A5 JP 2019567677 A JP2019567677 A JP 2019567677A JP 2019567677 A JP2019567677 A JP 2019567677A JP 2020522269 A5 JP2020522269 A5 JP 2020522269A5
Authority
JP
Japan
Prior art keywords
nucleic acid
recombinant nucleic
binding site
mir
mirna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019567677A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020522269A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/036200 external-priority patent/WO2018226785A1/en
Publication of JP2020522269A publication Critical patent/JP2020522269A/ja
Publication of JP2020522269A5 publication Critical patent/JP2020522269A5/ja
Priority to JP2023135189A priority Critical patent/JP2023164447A/ja
Pending legal-status Critical Current

Links

JP2019567677A 2017-06-06 2018-06-06 レット症候群におけるmecp2の安全な発現のための自己調節aavベクター Pending JP2020522269A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023135189A JP2023164447A (ja) 2017-06-06 2023-08-23 レット症候群におけるmecp2の安全な発現のための自己調節aavベクター

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762516060P 2017-06-06 2017-06-06
US62/516,060 2017-06-06
PCT/US2018/036200 WO2018226785A1 (en) 2017-06-06 2018-06-06 Self-regulating aav vectors for safe expression of mecp2 in rett syndrome

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023135189A Division JP2023164447A (ja) 2017-06-06 2023-08-23 レット症候群におけるmecp2の安全な発現のための自己調節aavベクター

Publications (2)

Publication Number Publication Date
JP2020522269A JP2020522269A (ja) 2020-07-30
JP2020522269A5 true JP2020522269A5 (enExample) 2021-07-26

Family

ID=64567243

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019567677A Pending JP2020522269A (ja) 2017-06-06 2018-06-06 レット症候群におけるmecp2の安全な発現のための自己調節aavベクター
JP2023135189A Pending JP2023164447A (ja) 2017-06-06 2023-08-23 レット症候群におけるmecp2の安全な発現のための自己調節aavベクター

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023135189A Pending JP2023164447A (ja) 2017-06-06 2023-08-23 レット症候群におけるmecp2の安全な発現のための自己調節aavベクター

Country Status (15)

Country Link
US (2) US11680275B2 (enExample)
EP (1) EP3635122A4 (enExample)
JP (2) JP2020522269A (enExample)
KR (1) KR20200015701A (enExample)
CN (1) CN111065742A (enExample)
AU (1) AU2018281145A1 (enExample)
BR (1) BR112019025732A2 (enExample)
CA (1) CA3066623A1 (enExample)
CL (1) CL2019003582A1 (enExample)
CO (1) CO2019014840A2 (enExample)
EA (1) EA201992882A1 (enExample)
IL (1) IL271170A (enExample)
MX (1) MX2019014760A (enExample)
SG (1) SG11201911737PA (enExample)
WO (1) WO2018226785A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10370432B2 (en) 2014-10-03 2019-08-06 University Of Massachusetts Heterologous targeting peptide grafted AAVS
EP3256170B1 (en) 2015-02-13 2020-09-23 University of Massachusetts Compositions and methods for transient delivery of nucleases
IL322146A (en) 2016-11-17 2025-09-01 Nationwide Childrens Hospital Inc Intrathecal administration of adenovirus encoding methyl-CpG-binding protein 2
FI3574091T3 (fi) 2017-01-30 2023-05-03 Brainvectis Ekspressiovektori kolesterolin 24-hydrolaasia varten polyglutamiinin toiston spinoserebellaariataksioiden hoidossa
MX2020010465A (es) 2018-04-03 2021-01-08 Vectores de virus para direccionamiento a tejidos oftalmicos.
CA3095179A1 (en) 2018-04-03 2019-10-10 Stridebio, Inc. Antibody-evading virus vectors
BR112020020266A2 (pt) 2018-04-03 2021-01-19 Stridebio, Inc. Vetores de vírus com evasão de anticorpos
CN113166208B (zh) 2018-10-02 2024-11-22 沃雅戈治疗公司 重新定向aav衣壳的嗜性
CN113727992A (zh) 2019-03-21 2021-11-30 斯特里迪比奥公司 重组腺相关病毒载体
WO2020219766A1 (en) * 2019-04-24 2020-10-29 The Trustees Of The University Of Pennsylvania Compositions useful in treatment of rett syndrome
EP3972631B1 (en) * 2019-05-21 2024-07-10 Institut National de la Santé et de la Recherche Médicale (INSERM) Expression vector for cholesterol 24-hydrolase in therapy of rett syndrome
MX2022004353A (es) 2019-10-17 2022-07-19 Casete de transferencia de aav.
CN114787180A (zh) 2019-10-17 2022-07-22 斯特里迪比奥公司 用于治疗c型尼曼-匹克病的腺相关病毒载体
KR20220107243A (ko) 2019-11-25 2022-08-02 코넬 유니버시티 Apoe 유전자 요법
US11891616B2 (en) 2019-12-05 2024-02-06 Board Of Regents Of The University Of Texas System Transgene cassettes designed to express a human MECP2 gene
WO2021183433A1 (en) * 2020-03-09 2021-09-16 University Of Massachusetts Gene replacement therapy for foxg1 syndrome
IL298138A (en) * 2020-05-12 2023-01-01 Univ Pennsylvania Compositions for drg-specific reduction of transgene expression
US12630842B2 (en) * 2020-05-13 2026-05-19 Voyager Therapeutics, Inc. Redirection of tropism of AAV capsids
MX2023000124A (es) * 2020-06-30 2023-03-08 Univ Court Univ Of Edinburgh Sistema de expresion de transgenes.
JP2023542614A (ja) * 2020-08-19 2023-10-11 サレプタ セラピューティクス, インコーポレイテッド レット症候群の治療のためのアデノ随伴ウイルスベクター
CN112194706B (zh) * 2020-09-30 2022-03-08 广州派真生物技术有限公司 腺相关病毒突变体及其应用
WO2022094078A1 (en) * 2020-10-28 2022-05-05 The Trustees Of The University Of Pennsylvania Compositions useful in treatment of rett syndrome
EP4426716A1 (en) 2021-11-02 2024-09-11 Voyager Therapeutics, Inc. Aav capsid variants and uses thereof
GB202201242D0 (en) * 2022-01-31 2022-03-16 Univ Edinburgh Recombinant optimized mecp2 cassettes and methods for treating rett syndrome and related disorders
KR20260016905A (ko) * 2023-03-22 2026-02-04 오스페달레 산 라파엘 에스.알.엘. 유전자 치료
CN121175427A (zh) * 2023-05-15 2025-12-19 上海金珂博生物技术有限公司 一种Rett综合症的基因治疗
AU2024285035A1 (en) * 2023-06-09 2026-01-15 Rinuagene Biotechnology Co., Ltd. Expression-adjustable engineered rna molecule

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
CN103589692B (zh) 2001-11-13 2018-07-24 宾夕法尼亚大学托管会 检测和/或鉴定腺伴随病毒(aav)序列以及分离所鉴定的新型序列的方法
US20040106566A1 (en) 2002-05-17 2004-06-03 Shi-Lung Lin RNA-splicing and processing-directed gene silencing and the relative applications thereof
KR20100089851A (ko) 2007-10-23 2010-08-12 노파르티스 아게 호흡기 질환의 치료를 위한 trkb 항체의 용도
JP5420568B2 (ja) * 2008-01-17 2014-02-19 アイアールエム・リミテッド・ライアビリティ・カンパニー 改良された抗TrkB抗体
WO2010105096A2 (en) 2009-03-11 2010-09-16 University Of Massachusetts Modulation of human cytomegalovirus replication by micro-rna 132 (mir132), micro-rna 145 (mir145) and micro-rna 212 (mir212)
NZ609640A (en) 2010-10-25 2015-06-26 Univ D’Aix Marseille Treatment of mecp2-associated disorders
US20160000794A1 (en) * 2012-09-25 2016-01-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Methods for the diagnosis and treatment of sjogren's syndrome
EP3564379A1 (en) 2013-09-13 2019-11-06 California Institute of Technology Selective recovery
WO2015127128A2 (en) 2014-02-19 2015-08-27 University Of Massachusetts Recombinant aavs having useful transcytosis properties
WO2015164786A1 (en) * 2014-04-25 2015-10-29 University Of Massachusetts Recombinant aav vectors useful for reducing immunity against transgene products
WO2016054557A1 (en) 2014-10-03 2016-04-07 University Of Massachusetts Novel high efficiency library-identified aav vectors
US10370432B2 (en) 2014-10-03 2019-08-06 University Of Massachusetts Heterologous targeting peptide grafted AAVS
WO2016065001A1 (en) 2014-10-21 2016-04-28 University Of Massachusetts Recombinant aav variants and uses thereof
US11046955B2 (en) 2015-04-24 2021-06-29 University Of Massachusetts Modified AAV constructs and uses thereof
EP3121284A1 (en) * 2015-07-22 2017-01-25 Ecole Polytechnique Fédérale de Lausanne (EPFL) Bicistronic aav vector for rna interference in als

Similar Documents

Publication Publication Date Title
JP7395550B2 (ja) 新規アデノ随伴ウイルスキャプシドタンパク質
JP2021106619A5 (enExample)
US20220331409A1 (en) Factor ix gene therapy
JP6619454B2 (ja) キャプシド
JP2024009857A5 (enExample)
JP2018522529A5 (enExample)
JP2021512649A5 (enExample)
JP2007507223A5 (enExample)
JP2022529631A5 (enExample)
RU2018116076A (ru) Модифицированные гены атаксии фридрейха и векторы для генной терапии
JP2018531609A5 (enExample)
JP2017509632A5 (enExample)
KR20160033217A (ko) 변종 aav 및 조성물, 세포, 기관 및 조직으로의 유전자 전이를 위한 방법 및 용도
JP2017529395A5 (enExample)
JP2020519284A5 (enExample)
JP7702949B2 (ja) ヒトmecp2遺伝子を発現するように設計されたトランスジーンカセット
JP2023524414A5 (enExample)
JP2023529371A5 (enExample)
JP2023537358A5 (enExample)
JP2020519294A5 (enExample)
JP2023553005A5 (enExample)
JP2023520927A5 (enExample)
FI3177313T3 (fi) Telomeraasi-käänteistranskriptaasipohjaisia hoitoja sydäninfarktiin liittyvien tilojen hoitamiseksi
JP2023541444A5 (enExample)
JP2022527126A5 (enExample)